BioSenic receives a Chinese patent with broad claims, protecting the combined use of metal ions and arsenic salts to treat a wide range of serious diseases
INSIDE INFORMATION...…
0,015€
5,82%
Echtzeit-Aktienkurs BONE THERAPEUTICS S.A.
Bid:
Ask:
Nachrichten zur BONE THERAPEUTICS S.A. Aktie
BioSenic S.A. : Information on the total number of voting rights and shares
REGULATED INFORMATION...…
BioSenic provides further update on negotiations with its main creditors
INSIDE INFORMATION...…
BioSenic S.A. : Information on the total number of voting rights and shares
REGULATED INFORMATION...…
BioSenic provides financial update
INSIDE INFORMATION...…
XFRA : BT1: Wiederaufnahme/Resumption
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…
BioSenic presents data on its new copper-arsenic trioxide combination for immunological disorders at the 25th International Conference on Redox Medicine
INSIDE INFORMATION...…
BioSenic puts Phase IIb ALLOB trial on hold
INSIDE INFORMATION...…
BioSenic SA : Information on the total number of voting rights and shares
REGULATED INFORMATION...…
BioSenic provides update regarding current license agreement with Phebra
INSIDE INFORMATION...…
BioSenic and Pluristyx sign term sheet for market availability of ALLOB mesenchymal cells
INSIDE INFORMATION...…
BioSenic provides First Quarter 2023 Business Update
REGULATED INFORMATION...…
BioSenic reacquires global IP rights and provides update on JTA-004 development
INSIDE INFORMATION...…
BioSenic to host Annual General Meeting on June 14 2023
REGULATED INFORMATION...…
BioSenic identifies key biomarkers for cGvHD and submits patent to EPO
INSIDE INFORMATION...…
BioSenic announces 2022 full year results
REGULATED INFORMATION ...…
BioSenic receives key European patent from EPO, for further therapeutic development in cancer, infectious and immune diseases
INSIDE INFORMATION...…
BioSenic appoints Lieven Huysse, MD, as Chief Medical Officer
INSIDE INFORMATION...…
BioSenic provides Financial Update and Financial Calendar 2023
INSIDE INFORMATION...…
BioSenic publishes new data on the mechanism of action of arsenic trioxide (ATO)
INSIDE INFORMATION...…
BioSenic delivers a new post-hoc analysis of its Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected patient population
REGULATED INFORMATION...…
BioSenic SA: Information on the total number of voting rights and shares
REGULATED INFORMATION...…
BioSenic optimizes statistical analysis for its ongoing ALLOB Phase IIb study for high-risk tibial fractures, requiring fewer patients and completes patient recruitment
Combination of advances in radiological assessments, new scientific insights in fracture healing and updated statistical analysis results in fewer patients…
BioSenic receives EUR 1 million from Pregene in accordance with terminated license agreement and expect new negotiations on common revisited grounds
Following the regaining of ALLOB global rights, BioSenic has received a final payment from Pregene linked to a previously achieved…
BioSenic announces initiation of coverage by Portzamparc and Gilbert Dupont
Mont-Saint-Guibert, Belgium, February 14, 2023, 5:45 pm CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing…
BioSenic announces the approval and publication of the Prospectus for listing and admission to trading of the shares and subscription rights issued in the context of the capital increase by way of in kind contributions of Medsenic
REGULATED INFORMATION...…
BioSenic SA : Information on the total number of voting rights and shares
REGULATED INFORMATION...…
BioSenic appoints Yves Sagot as Independent Director
REGULATED INFORMATION...…
BioSenic appoints Dr Carole Nicco as Chief Scientific Officer
Dr Nicco will oversee the development of pipeline across BioSenics cell therapy and...…
BioSenic SA : Information on the total number of voting rights and shares
REGULATED INFORMATION...…
XFRA : BT1: Wiederaufnahme/Resumption
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…
XFRA : BT1: Aussetzung/Suspension
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME …
XFRA : INSTRUMENT_SUSPENSION - BE0974280126
Instrument ID [1383] (BT1 - BE0974280126) suspended...…
Bone Therapeutics to start a new Euronext equity story with a change of name to BioSenic, following the acquisition of a majority participation of Medsenic valued at EUR 40 million
REGULATED INFORMATION...…
Bone Therapeutics provides Third Quarter 2022 Business Update
REGULATED INFORMATION...…
Bone Therapeutics SA: Transparency notification received from S.F.P.I/F.P.I.M
REGULATED INFORMATION...…
Bone Therapeutics to regain worldwide rights to ALLOB
INSIDE INFORMATION...…
Bone Therapeutics to host Extraordinary General Meeting on 24 October 2022
REGULATED INFORMATION...…